See Semax dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
Semax is an ACTH-derived nootropic peptide researched for its neuroprotective and cognitive-enhancing properties. This data shows the dose amounts, vial sizes, and diluent volumes researchers most commonly select in the WPA calculator when preparing Semax for subcutaneous or intranasal administration.
Semax is a synthetic heptapeptide engineered at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s by the group around Ivan Ashmarin and Nikolai Myasoedov. The structure is the ACTH 4-7 fragment (Met-Glu-His-Phe) extended at the C-terminus with a Pro-Gly-Pro tripeptide tail that strips out the corticotropic activity of native ACTH while stabilizing the molecule against enzymatic degradation in the nasal mucosa. The Russian published record is substantial — Ashmarin, Myasoedov, and Levitskaya ran the foundational pharmacology and clinical work through the 1990s and 2000s — and Semax sits on the Russian Federation's essential medicines list with formal indications in ischemic stroke recovery, optic nerve atrophy, and cognitive deficit at intranasal doses ranging from roughly 200-2000mcg/day depending on indication.
Semax is a nootropic and neuroprotective research peptide most often sourced for focus, cognition, and recovery protocols, and used intranasally. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.
Semax binds melanocortin receptors with low affinity and notably lacks the cortisol-releasing activity of full-length ACTH. Its dominant pharmacology is up-regulation of brain-derived neurotrophic factor (BDNF) and its TrkB receptor in hippocampus and cortex, together with modulation of dopaminergic, serotonergic, and enkephalin tone — effects attributed both to the parent fragment and to its glyproline metabolite.
Russian clinical work has evaluated Semax in acute ischemic stroke (Gusev/Skvortsova cohorts reporting reduced neurological deficit when dosed within 6h of onset), optic-nerve atrophy, and ADHD in school-age children. No Western Phase 2/3 trials have been published, and outside Russia Semax is sold strictly as a research peptide.
Semax has a reported half-life of ~30 min, and the dose intervals researchers model most often fall around twice daily (intranasal). Very short plasma half-life. Semax acts as a pulse rather than building to a steady level; frequency and consistency of dosing matter more than total daily amount. It is catalogued under Memory Peptides on WPA.
1,871 Semax reconstitution calculations have been logged by the WPA community. The most common dose entered is 300mcg (391 calculations). The most common bacteriostatic water volume is 3mL. The most popular vial size is 10mg (1,222 sessions). The most common dosing frequency is daily (7x/week) (230 logged protocols), followed by once weekly (67).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.